DSIP (5 mg Vial)

DSIP Dosage Chart

DSIP (Delta Sleep-Inducing Peptide) is commonly studied in educational and research protocols at doses ranging from 100–300 mcg daily by subcutaneous injection, typically administered before bedtime.

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide composed of nine amino acids. It was first isolated from brain tissue and has been widely studied for its potential role in sleep regulation, stress response, and neuroendocrine function. Preclinical and limited clinical research suggests that DSIP may help support slow-wave (delta) sleep, influence the regulation of stress-related hormones such as cortisol and ACTH, and contribute to the body’s natural response to physical and mental stress. Ongoing research has also explored its potential effects on recovery, circadian rhythm, and overall neurological function. This protocol outlines a once-daily subcutaneous administration approach using a practical dilution designed to provide clear and consistent insulin syringe measurements.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week/Phase	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1	100 mcg	6 units (0.06 mL)
Weeks 2	150 mcg	9 units (0.09 mL)
Weeks 2	200 mcg	12 units (0.12 mL)
Weeks 4-8	250–300 mcg	15–18 units (0.15–0.18 mL)

– Frequency: Administer one subcutaneous injection daily, typically in the evening before bedtime. – Syringe Selection: For doses requiring 10 units (0.10 mL) or less—such as those commonly used during the initial weeks—a 30-unit or 50-unit U-100 insulin syringe may provide easier and more accurate measurement.

Advanced / Extended Approach

Note: Higher-dose protocols (above 300 mcg daily) have limited clinical evidence and are supported primarily by anecdotal reports. When following a titration approach, begin with the lowest planned dose and increase only if appropriate for the intended protocol.

Reconstitution Steps

1. Draw 3.0 mL of bacteriostatic water using a sterile syringe.
2. Inject the water slowly down the inside wall of the vial to help minimize foaming.
3. Gently swirl or roll the vial until the powder has completely dissolved. Do not shake the vial.
4. Label the vial with the reconstitution date and store it refrigerated at 2–8 °C (35.6–46.4 °F), protected from direct light.

mportant: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–12 week daily protocol with gradual titration.

A concise overview of the once-daily DSIP protocol.

Goal: Support healthy sleep architecture and the body's natural stress response over time.
Schedule: One subcutaneous injection daily for 4–8 weeks, with the option to continue for up to 12 weeks if desired.
Dose Range: 100–300 mcg daily with gradual titration. Some research protocols evaluate doses of up to 500 mcg.
Reconstitution: Reconstitute each 5 mg vial with 3.0 mL of bacteriostatic water to achieve an approximate concentration of 1.67 mg/mL for accurate dosing.
Storage: Store lyophilized vials frozen until use. After reconstitution, refrigerate and avoid repeated freeze–thaw cycles.

A suggested daily titration approach for the planned protocol.

Starting Dose: 100 mcg once daily.
Titration: Increase the dose by approximately 50 mcg every 1–2 weeks, if following a gradual titration plan.
Target Dose: 250–300 mcg once daily by Weeks 4–8.
Frequency: One subcutaneous injection per day, typically administered before bedtime.
Cycle Length: Standard protocol is 4–8 weeks, with an optional extension to 12 weeks that may include periodic breaks.
Timing: Evening administration is preferred. Rotate injection sites regularly to support consistent injection practices.

Proper storage helps maintain peptide stability and quality.

Lyophilized Vials: Store at −20 °C (−4 °F) in a dry, dark environment and minimize exposure to moisture.
Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F). Use within approximately 4 weeks and avoid repeated freeze–thaw cycles.
Before Opening: Allow the vial to reach room temperature before opening to help minimize condensation inside the vial.

Practical considerations to help maintain consistency throughout the protocol.

Use a new sterile insulin syringe for each injection and dispose of used syringes in an appropriate sharps container.
Rotate injection sites (such as the abdomen, thighs, and upper arms) to help reduce local irritation.
Inject slowly and wait a few seconds before withdrawing the needle.
Keep a daily record of the dose administered and the injection site used to maintain consistency throughout the protocol.
Response to DSIP may vary. Some research suggests its effects may extend beyond the day of administration in certain individuals. Follow the planned protocol and adjust only if appropriate for the intended dosing schedule.

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring nonapeptide that was first identified as a peptide associated with sleep regulation. It has been studied for its potential role in supporting healthy sleep patterns and neuroendocrine function. Preclinical and limited clinical research suggests that DSIP may help regulate sleep through its interactions with GABAergic signaling and other neurotransmitter systems. Studies have also explored its potential to support slow-wave (delta) sleep without substantially affecting normal REM sleep architecture. Beyond its potential effects on sleep, DSIP has been investigated for its stress-supportive and adaptogenic properties. Research suggests these effects may be related to its influence on the body’s neuroendocrine system, including pathways involved in the normal stress response.

Observations from preclinical and clinical literature.

May help support deeper, more restorative slow-wave sleep and improve overall sleep quality.
Research suggests potential stress-supportive and anxiolytic-like effects in certain study models.
Some studies indicate that DSIP may not produce significant pharmacological tolerance with continued use.
DSIP has generally been well tolerated in available human studies.
Some individuals may experience mild injection-site reactions, such as temporary redness, itching, or minor irritation following subcutaneous administration.
Long-term safety data remain limited. Periodic breaks may be considered as part of longer research protocols.

Complementary strategies for best outcomes.

Maintain consistent sleep-wake schedules to reinforce circadian rhythms.
Limit blue light exposure and stimulants (caffeine, nicotine) in the hours before bed.
Create a cool, dark, quiet sleep environment.
Incorporate regular physical activity, ideally earlier in the day.
Manage stress through relaxation techniques (meditation, deep breathing).

General guidance for subcutaneous injection based on established clinical best practices.

Clean the vial stopper and the injection site with an alcohol swab, then allow both to dry completely before injecting.
Pinch a fold of skin and insert the needle into the subcutaneous tissue at a 45°–90° angle, depending on the injection site and needle length.
Inject slowly and steadily. Aspiration is generally not required for subcutaneous injections.
Rotate injection sites regularly (such as the abdomen—at least 2 inches (5 cm) away from the navel—thighs, and upper arms) to help minimize local irritation and reduce the risk of tissue changes with repeated injections.

Product Quality Considerations

This content is for educational purposes only and is not medical advice.

Schoenenberger GA, Monnier M (1977)

— Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA

European Journal of Anaesthesiology (2001)

— Delta sleep-inducing peptide: editorial review of mechanisms and clinical context

Schneider-Helmert D, Schoenenberger GA (1983)

— Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology

Sudakov KV et al. (2004)

— Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci

Schneider-Helmert D (1981)

— Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol

Graf MV, Kastin AJ (1984)

Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev

Iyer KS et al. (1988)

Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol

Manning MC et al. (2010)

Stability of protein pharmaceuticals: an update. Pharm Res

Wang W (2000)

Lyophilization and development of solid protein pharmaceuticals. Int J Pharm

Yehuda S, Carasso RL (1988)

DSIP: brain mechanisms and function. Int J Neurosci

Khvatova EM et al. (2003)

— Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med

CDC

Vaccine administration: subcutaneous route (angle/site; no aspiration)

NCBI Bookshelf

Medication Administration: Subcutaneous Injections (Open RN Nursing Skills)

Vitality Labs Peptides

DSIP (5 mg) product page (quality and batch documentation)